Amicus Therapeutics

Privately held: no public share price

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Migalastat(Galafold)
Approved
Alpha-galactosidase A (GLA / α-Gal A)Small molecule
Fabry Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Migalastat · GalafoldPhase 3Fabry Disease
Est. primary completion 2026-12-31 · NCT04020055 · CT.gov ↗
What to watch
2027 (1)
December 2027 (1)
Migalastat · GalafoldPhase 3Fabry Disease
Est. primary completion 2027-12 · NCT06904261 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.